Stem Cell Therapy for Lyme Disease: An Honest Evidence Review

At a Glance

I need to start this article with a statement of position, because the topic demands it.

Stem cell therapy for Lyme disease is one of the fastest-growing segments of regenerative medicine marketing. Patient interest is surging — search volume for “stem cell therapy Lyme disease” has increased substantially over the past two years. Clinics in Mexico, Panama, Colombia, Thailand, and parts of Europe are marketing stem cell treatments for Lyme patients, often at prices between $15,000 and $50,000 per course.

Here is my concern: the marketing has far outpaced the evidence. As a physician who treats chronic Lyme disease as a core part of my practice — using whole-body hyperthermia, H.E.L.P. apheresis, targeted antimicrobials, and immune support — I am deeply interested in any therapy that could help my patients. But I am also deeply uncomfortable when patients spend $30,000-50,000 on treatments supported by marketing claims rather than clinical evidence.

This article is my honest assessment of where stem cell therapy stands for Lyme disease in 2026: what we know, what we do not know, what makes biological sense, and what should concern you.

The Theoretical Case for Stem Cells in Lyme Disease

Before I discuss the evidence limitations, I want to acknowledge that the theoretical rationale for stem cells in chronic Lyme disease is not unreasonable. It is based on real biology — the problem is that it has not been validated in clinical trials specific to Lyme.

What Chronic Lyme Disease Does to the Body

Chronic Lyme disease causes damage through several mechanisms:

Persistent inflammation. Even after the Borrelia organisms are eradicated or suppressed, chronic inflammation often persists. Inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) remain elevated. Neuroinflammation can persist for months after microbiological clearance. This ongoing inflammation drives many of the symptoms patients experience — fatigue, brain fog, joint pain, neuropathy.

Tissue damage. Borrelia’s inflammatory response damages joints, nervous tissue, cardiac tissue, and connective tissue. This damage does not automatically reverse when the infection is treated. Some patients are left with structural damage that drives ongoing symptoms even after successful antimicrobial therapy.

Immune dysregulation. Chronic Borrelia infection dysregulates the immune system — suppressing protective Th1 responses while enhancing autoimmune-prone Th17 pathways. Some researchers hypothesize that post-treatment Lyme symptoms are partly driven by autoimmune mechanisms triggered by the infection but persisting after the pathogen is cleared [1].

Mitochondrial dysfunction. Chronic infection and inflammation impair mitochondrial energy production. This likely contributes to the crushing fatigue that characterizes chronic Lyme disease.

What Mesenchymal Stem Cells Do

Mesenchymal stem cells (MSCs) — the type most commonly used in regenerative medicine — have documented biological properties that are theoretically relevant to these post-Lyme pathologies:

Anti-inflammatory effects. MSCs secrete anti-inflammatory cytokines (IL-10, TGF-beta) and suppress pro-inflammatory pathways. This is well-documented in autoimmune conditions like graft-versus-host disease, Crohn’s disease, and rheumatoid arthritis [2].

Immunomodulation. MSCs modulate T-cell function, promote regulatory T-cell development, and can shift immune responses from pro-inflammatory to regulatory phenotypes. In theory, this could address the immune dysregulation seen in chronic Lyme.

Tissue repair. MSCs support tissue regeneration through paracrine signaling — they secrete growth factors that promote angiogenesis, reduce fibrosis, and support local stem cell activation. This is relevant for damaged joints, nerves, and connective tissue. Researchers have since identified that much of this paracrine benefit is carried by exosomes—the nano-sized vesicles MSCs release into circulation; exosome therapy captures this signalling fraction directly and may provide a targeted alternative for post-infectious tissue repair in patients who are not candidates for whole-cell transplantation.

Neuroprotective effects. MSCs have shown neuroprotective properties in preclinical models of neuroinflammation, reducing microglial activation and supporting neuronal survival [3].

On paper, this looks promising. An intervention that is anti-inflammatory, immunomodulatory, tissue-reparative, and neuroprotective sounds like it should help chronic Lyme patients.

The problem is the gap between mechanistic rationale and clinical proof.

The Evidence: What Actually Exists

Let me be specific about the evidence landscape, because specificity matters when patients are making decisions about expensive treatments.

Published RCTs for Stem Cells in Lyme Disease

There are none. As of April 2026, I am not aware of any published randomized controlled trial evaluating stem cell therapy specifically for chronic Lyme disease or post-treatment Lyme disease syndrome (PTLDS). Zero.

This does not mean the treatment is ineffective. Absence of evidence is not evidence of absence. But it does mean that any clinic claiming “clinically proven” stem cell therapy for Lyme is misrepresenting the evidence base.

Published Case Reports and Case Series

There are scattered case reports and small case series describing stem cell treatment in chronic Lyme patients, primarily from clinics that offer the therapy. These reports generally show:

• Patient-reported symptom improvement (fatigue, pain, cognitive function)
• Variable follow-up durations (weeks to months)
• No control groups
• No blinding
• Significant selection bias (patients who self-select for expensive treatment are not representative)

Case reports are the lowest tier of clinical evidence. They can generate hypotheses worth testing but cannot establish efficacy.

Evidence From Related Conditions

The strongest supporting evidence comes from stem cell research in conditions that share pathological features with chronic Lyme:

Autoimmune conditions: MSC therapy has been studied in RCTs for rheumatoid arthritis, Crohn’s disease, multiple sclerosis, and systemic lupus erythematosus. Results are mixed but generally show modest anti-inflammatory benefit in some patients [4]. The most robust data is for perianal fistulizing Crohn’s disease (the product Alofisel/darvadstrocel received EMA approval).

Neuroinflammation: Preclinical studies show MSC-mediated reduction in neuroinflammation markers. Early-phase clinical trials in multiple sclerosis and ALS have demonstrated safety and some signal of efficacy, though results are not definitive [5].

Osteoarthritis: MSC injections for knee osteoarthritis have the most clinical trial data of any musculoskeletal application. Results show modest improvement in pain and function compared to controls, though the evidence is heterogeneous and effect sizes are moderate.

These adjacent data points suggest that MSCs have genuine biological activity relevant to chronic Lyme pathology. But extrapolating from rheumatoid arthritis studies to Lyme disease claims is a significant inferential leap.

What Concerns Me About the Current Landscape

The Cost-Evidence Mismatch

When a treatment costs $20,000-50,000 per course and has no published RCTs for the condition being treated, the economic incentive to promote the treatment is enormous relative to the evidence supporting it. This creates a dynamic where marketing investment exceeds research investment — the opposite of how medicine should work.

I am not suggesting that every clinic offering stem cells for Lyme is acting in bad faith. Some are run by well-intentioned physicians who believe in the theoretical rationale and have observed positive outcomes in their patients. But patient testimonials and clinical impressions, however sincere, are not a substitute for controlled trials. We have learned this lesson repeatedly throughout medical history.

Stem Cell Tourism Red Flags

The stem cell tourism industry — clinics in countries with less regulatory oversight marketing to desperate patients from countries with stricter regulations — has specific patterns that patients should recognize:

“Guaranteed results” or cure claims. No legitimate medical treatment guarantees outcomes. Any clinic promising to cure your chronic Lyme disease with stem cells is making a claim that the evidence does not support.

Vague descriptions of the cell product. What type of stem cells? From what source (autologous bone marrow, adipose tissue, umbilical cord, amniotic membrane)? What is the cell count? What quality testing is performed? How are the cells processed, expanded, and stored? If the clinic cannot answer these questions specifically, you do not know what you are paying for.

No pre-treatment evaluation. Responsible stem cell therapy requires comprehensive evaluation — active infection status, immune panel, inflammatory markers, imaging of target tissues. If a clinic is willing to inject stem cells without thorough assessment, the treatment is protocol-driven, not patient-driven.

No follow-up plan. What happens after the injection? What monitoring is planned? What do you do if symptoms do not improve? A clinic that collects payment and sends you home with no structured follow-up is not providing medical care — it is providing a procedure.

Extravagant patient testimonial marketing. Video testimonials of patients declaring themselves cured are powerful emotionally but meaningless scientifically. Placebo response rates for interventional procedures are 30-40%. Post-hoc testimonials cannot distinguish between placebo response, natural disease fluctuation, and genuine treatment effect.

The Active Infection Question

This is a critical clinical issue that is often overlooked in stem cell marketing. MSCs are immunomodulatory — they suppress inflammatory and immune responses. If a chronic Lyme patient has active, ongoing Borrelia infection (not just post-infectious inflammation), suppressing the immune response with MSCs could theoretically make the infection worse by reducing the immune pressure keeping the organisms in check.

This is not a theoretical concern. It reflects a fundamental question about the pathology of chronic Lyme: is the patient’s suffering driven by active infection, post-infectious autoimmunity, or both? The treatment approach differs dramatically depending on the answer.

In my clinical experience, most chronic Lyme patients have a combination of residual active infection and post-infectious pathology. Treating the active infection first — through appropriate antimicrobials and, where indicated, whole-body hyperthermia — and then addressing residual tissue damage and immune dysregulation is, in my view, a more logical sequence than jumping directly to immunomodulatory stem cell therapy while the infection may still be active.

Where Stem Cells Might Have a Legitimate Role

Despite my concerns about premature marketing, I want to be fair about where I think stem cell therapy may eventually prove useful for Lyme patients:

Post-Eradication Tissue Repair

After the infection has been adequately treated — through antibiotics, hyperthermia, or both — some patients are left with tissue damage that drives persistent symptoms. Damaged cartilage, nerve injury, chronic tendon and ligament changes. In these cases, the problem is no longer infection or immune dysregulation — it is structural damage. MSC therapy has its most established evidence base precisely in this domain (osteoarthritis, tendon repair, nerve regeneration). Using stem cells for post-eradication tissue repair is a more evidence-supported application than using them as a primary Lyme treatment.

Post-Infectious Autoimmune Dysregulation

If a subset of chronic Lyme patients has autoimmune-driven symptoms that persist after microbial clearance — analogous to post-streptococcal autoimmune disorders — then MSC immunomodulation could have a logical therapeutic role. This would require first confirming that the infection is cleared (through reliable testing and/or eradication therapy) and then documenting autoimmune markers. This is a research hypothesis worth testing in a clinical trial, not a marketing claim worth billing $30,000 for.

Neuroregeneration

The neuroprotective and neuroregenerative potential of MSCs is being studied across multiple neurological conditions. For Lyme patients with documented neurological damage (neuroborreliosis, peripheral neuropathy, cognitive impairment), MSC-based neuroregenerative approaches may eventually become part of the treatment landscape. The evidence is early-phase and the timeline for clinical validation is measured in years, not months.

What I Recommend Instead — and Why

When patients ask me about stem cells for their chronic Lyme disease, here is the conversation I have:

First: treat the infection adequately. If Borrelia and/or co-infections are still active, address them with proven approaches — targeted antibiotics, and where indicated, whole-body hyperthermia. Stem cells are not an antimicrobial therapy.

Second: address the inflammatory cascade. H.E.L.P. apheresis removes inflammatory proteins, fibrinogen, and circulating toxins directly. IV laser therapy (photobiomodulation) modulates immune function and improves circulation. These are treatments with documented mechanisms and clinical track records in our patient population.

Third: support tissue repair through established methods. Peptide therapy (where regulatory frameworks permit), targeted nutrient repletion, physical rehabilitation, and time. The body has remarkable regenerative capacity when the drivers of damage (active infection, chronic inflammation) are removed.

Fourth: if structural tissue damage persists after adequate treatment of infection and inflammation, consider MSC therapy as an adjunctive approach — ideally within a clinical trial or at a facility with transparent outcomes data, rigorous quality control, and appropriate follow-up.

This is not an anti-stem-cell position. It is a sequencing position. Stem cells may have a role in the Lyme treatment landscape. But that role is most logically after infection eradication, not instead of it — and certainly not at the current price points charged by clinics that cannot point to controlled clinical evidence.

Questions to Ask Before Considering Stem Cell Therapy for Lyme

If you decide to pursue stem cell therapy despite the evidence limitations, ask these questions:

1. Can you show me published clinical trial data for this specific application? Not case reports. Not testimonials. Published trial data.
2. What type of stem cells are being used, and what is the cell count per dose? The answer matters because different cell types and doses have different biological effects.
3. Has my active infection been adequately addressed? If not, immunomodulatory therapy may be contraindicated.
4. What quality testing is performed on the cell product? Viability testing, sterility testing, identity confirmation, potency assay — these are minimum standards.
5. What is the complication rate at this facility? Any honest provider can answer this with data.
6. What follow-up monitoring is included? If none, the clinic is selling a procedure, not providing care.
7. What happens if it does not work? A responsible provider has a plan for treatment failure.

My Bottom Line

Stem cell therapy for Lyme disease is an area where patient desperation, biological plausibility, and commercial incentive have converged to create a market that is currently ahead of its evidence base. The theoretical rationale is sound. The clinical evidence is insufficient. The cost is high. The risk of exploitation is real.

I tell my patients this: I am watching the stem cell literature closely. When controlled clinical evidence emerges that demonstrates efficacy for specific Lyme-related pathologies, I will incorporate it into our treatment protocols. Until then, I will continue to use treatments that have established evidence and documented clinical track records — and I will be honest about the distinction.

That honesty is the least patients deserve when they are suffering and searching for answers.

References

1. Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest. 2012;122(7):2652-2660.
2. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736.
3. Volkman R, Offen D. Concise review: mesenchymal stem cells in neurodegenerative diseases. Stem Cells. 2017;35(8):1867-1880.
4. Wang L, Zhao Y, Shi S. Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. J Dent Res. 2012;91(8):927-931.
5. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150-156.
6. Peeters CM, Leijs MJ, Reijman M, et al. Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review. Osteoarthritis Cartilage. 2013;21(10):1465-1473.
7. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19(2):154-157.